Literature DB >> 12874736

Developing high-quality interventions for posttraumatic stress disorder in the acute care medical setting.

Douglas Zatzick1, Peter Roy-Byrne.   

Abstract

The secondary prevention of posttraumatic stress disorder (PTSD) and related comorbidities among injured trauma survivors constitutes an important public health problem. This article outlines quality-of-care criteria that are intended to guide intervention development for PTSD in the acute care medical setting. The multiple demographic, injury, and service delivery system factors that characterize the acute care setting's clinical heterogeneity are discussed. A model of intervention development that begins with population-based descriptive studies and small pilots of efficacious PTSD treatments and evolves to the development of larger-scale multifaceted collaborative interventions is introduced. Collaborative interventions hold promise for injured trauma survivors treated in acute care settings because they combine evidence-based PTSD interventions and patient-centered supportive care. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12874736     DOI: 10.1016/s1084-3612(03)00016-9

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  3 in total

1.  Prevalence of posttraumatic stress disorder and major depression after trauma center hospitalization.

Authors:  Regina A Shih; Terry L Schell; Katrin Hambarsoomian; Howard Belzberg; Grant N Marshall
Journal:  J Trauma       Date:  2010-12

2.  Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats.

Authors:  James Lim; Miki Igarashi; Kwang-Mook Jung; Stefania Butini; Giuseppe Campiani; Daniele Piomelli
Journal:  Neuropsychopharmacology       Date:  2015-09-11       Impact factor: 7.853

3.  Mental health service utilization after physical trauma: the importance of physician referral.

Authors:  Eunice C Wong; Terry L Schell; Grant N Marshall; Lisa H Jaycox; Katrin Hambarsoomians; Howard Belzberg
Journal:  Med Care       Date:  2009-10       Impact factor: 2.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.